Gene Solutions, in partnership with Gene Health, has launched SPOT-MAS in Taiwan, an AI-driven multi-cancer early detection (MCED) solution designed to identify cancer signals in asymptomatic individuals.

• Multi-Omics Technology: The test utilises a single blood draw to analyse cell-free DNA (cfDNA), integrating genetic, epigenetic, and fragmentomic features.
• AI Integration: Proprietary algorithms process multiple biological signals to enhance detection sensitivity and predict the specific organ system of origin.
• Clinical Scope: The screening is designed to complement existing traditional methods by identifying signals for common cancers that may not present symptoms in early stages.

This summary is based on a press release issued by Gene Solutions Genomics Pte Ltd.